<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">glaucoma</journal-id><journal-title-group><journal-title xml:lang="ru">Национальный журнал Глаукома</journal-title><trans-title-group xml:lang="en"><trans-title>National Journal glaucoma</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-4104</issn><issn pub-type="epub">2311-6862</issn><publisher><publisher-name>Federal State Budgetary Institution of Science “Krasnov Research Institute of Eye Diseases”</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.53432/2078-4104-2023-22-2-62-70</article-id><article-id custom-type="elpub" pub-id-type="custom">glaucoma-456</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Роль оптической когерентной томографии переднего отрезка глаза в выявлении предикторов офтальмогипертензии при анти-VEGF терапии</article-title><trans-title-group xml:lang="en"><trans-title>The role of anterior segment optical coherence tomography in the detection of predictors of ophthalmic hypertension associated with anti-VEGF injections</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8319-926X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андреева</surname><given-names>Ю. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Andreeva</surname><given-names>Y. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андреева Юлия Сергеевна - аспирант отдела патологии сетчатки и зрительного нерва</p><p>119021, Москва, ул. Россолимо, 11А</p></bio><bio xml:lang="en"><p>postgraduate student at the Department of Retina and Optic Nerve Pathology</p><p> 11A Rossolimo St., Moscow, 119021</p></bio><email xlink:type="simple">juliu95@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6791-4219</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алхарки</surname><given-names>Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Alharki</surname><given-names>L.</given-names></name></name-alternatives><bio xml:lang="ru"><p> к.м.н., научный сотрудник отдела витреоретинальной патологии</p><p>119021, Москва, ул. Россолимо, 11А</p></bio><bio xml:lang="en"><p>Cand. Sci. (Med.), researcher at the Department of Vitreoretinal Pathology</p><p> 11A Rossolimo St., Moscow, 119021</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1507-5094</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шеланкова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shelankova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., научный сотрудник отдела патологии сетчатки и зрительного нерва</p><p>119021, Москва, ул. Россолимо, 11А</p></bio><bio xml:lang="en"><p>Cand. Sci. (Med.), researcher at the Department of Retina and Optic Nerve Pathology</p><p> 11A Rossolimo St., Moscow, 119021</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5507-8775</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Будзинская</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Budzinskaya</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., главный научный сотрудник отдела патологии сетчатки и зрительного нерва</p><p>119021, Москва, ул. Россолимо, 11А</p></bio><bio xml:lang="en"><p>Dr. Sci. (Med.), chief researcher at the Department of Retina and Optic Nerve Pathology</p><p> 11A Rossolimo St., Moscow, 119021</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБНУ «НИИГБ им. М.М. Краснова»<country>Россия</country></aff><aff xml:lang="en">Krasnov Research Institute of Eye Diseases<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>12</day><month>05</month><year>2023</year></pub-date><volume>22</volume><issue>2</issue><fpage>62</fpage><lpage>70</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Андреева Ю.С., Алхарки Л., Шеланкова А.В., Будзинская М.В., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Андреева Ю.С., Алхарки Л., Шеланкова А.В., Будзинская М.В.</copyright-holder><copyright-holder xml:lang="en">Andreeva Y.S., Alharki L., Shelankova A.V., Budzinskaya M.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.glaucomajournal.ru/jour/article/view/456">https://www.glaucomajournal.ru/jour/article/view/456</self-uri><abstract><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ. Выявить с использованием оптической когерентной томографии переднего отрезка глаза (AS-OCT) предикторы повышения внутриглазного давления (ВГД) после интравитреальной инъекции (ИВИ) анти-VEGF препарата и изучить изменения иридо-хрусталиковой диафрагмы на фоне многократных инъекций при лечении неоваскулярной формы возрастной макулярной дегенерации (нВМД).</p></sec><sec><title>МЕТОДЫ</title><p>МЕТОДЫ. В исследование было включено 30 пациентов с впервые диагностированной нВМД. ВГД измеряли тонометром ICare Pro до ИВИ, через 1 минуту после ИВИ, затем через 30, 60 и 180 минут. При помощи томографа Revo NX (Optopol, Польша) оценивали глубину передней камеры (ГПК), размеры угла передней камеры (УПК) и толщину хрусталика. Исследование проводили до ИВИ, через месяц после первой ИВИ, через месяц после третьей ИВИ и через год после начала лечения. Исследование переднезадней оси глаза (ПЗО) проводили однократно до ИВИ.</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Была найдена обратная корреляция между ПЗО и повышением ВГД через 1 минуту после ИВИ (rxy=0,65; p&lt;0,001). Через год от начала лечения на фоне анти-VEGF терапии по данным AS-ОCТ было определено достоверное уменьшение ГПК по сравнению с данными до лечения (р&gt;&lt;0,001), а также уменьшение всех параметров УПК (р&gt;&lt;0,05). Меньшие размеры ПЗО (R2 =0,45; p&gt;&lt;0,05), меньшая ГПК (R2 =0,44; p&gt;&lt;0,05), меньшие размеры УПК с носовой (R2 =0,37; p&gt;&lt;0,05) и височной стороны (R2 =0,39; p&gt;&lt;0,05) приводили у пациентов с собственным хрусталиком к большему подъему ВГД через 1 мин после ИВИ.</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. К предикторам резкого повышения ВГД после ИВИ анти-VEGF препарата у пациентов с нВМД по данным AS-ОCТ относятся меньшие размеры ГПК и УПК. Выявлена прогностическая модель — при уменьшении размеров ПЗО на 1 мм следует ожидать увеличения ВГД на 2,3 мм рт.ст., уменьшение УПК с височной стороны на 1° ведет к увеличению ВГД на 0,28 мм рт.ст&gt;</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>PURPOSE</title><p>PURPOSE. To identify the predictors of increased intraocular pressure (IOP) after intravitreal injection (IVI) of an antiVEGF drug using anterior segment optical coherence tomography (AS-OCT), and to study changes in the iris-lens diaphragm produced by multiple injections in the treatment of neovascular form of age-related macular degeneration (nAMD).</p></sec><sec><title>METHODS</title><p>METHODS. IOP was measured with an ICare Pro tonometer before IVI, 1 minute after IVI, 30 minutes, 60 minutes and 180 minutes later. Anterior chamber depth (ACD), anterior chamber angle (ACA), and lens thickness were assessed using Revo NX tomograph (Optopol, Poland). The study was carried out before IVI, one month after the first IVI, one month after the third IVI, one year after the start of treatment. Axial length was measured once before IVI.</p></sec><sec><title>RESULTS</title><p>RESULTS. An inverse correlation was found between axial length and an increase in IOP 1 min after IVI (r=0.65, p&lt;0.001). According to AS-OCT data, one year after the start of treatment there was a significant decrease in ACD compared to the data before treatment (p&gt;&lt;0.001), as well as a decrease in all parameters of ACA (p&gt;&lt;0.05). Shorter axial length (R2 =0.45, p&gt;&lt;0.05), shorter ACD (R2 =0.44, p&gt;&lt;0.05), smaller ACA on the nasal (R2 =0.37, p&gt;&lt;0.05) and temporal (R2 =0.39, p&gt;&lt;0.05) sides in patients with their own lens led to a greater rise in IOP 1 min after IVI.</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION. Predictors of a sharp increase in IOP after IVI of an anti-VEGF drug in patients with nAMD that can be detected with AS-OCT are shorter ACD and smaller ACA. The following prognostic model was determined — with a 1-mm decrease in the axial length, an increase in IOP by 2.3 mm Hg should be expected, a decrease in ACA from the temporal side by 1° leads to an increase in IOP of 0.28 mm Hg&gt;</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>внутриглазное давление</kwd><kwd>антиVEGF</kwd><kwd>оптическая когерентная томография переднего отрезка</kwd><kwd>возрастная макулярная дегенерация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>intraocular pressure</kwd><kwd>anti-VEGF drugs</kwd><kwd>anterior segment optical coherence tomography</kwd><kwd>age-related macular degeneration</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular agerelated macular degeneration. N Engl J Med 2011; 364:1897-908. https://doi.org/10.1056/NEJMoa1102673</mixed-citation><mixed-citation xml:lang="en">CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular agerelated macular degeneration. N Engl J Med 2011; 364:1897-908. https://doi.org/10.1056/NEJMoa1102673</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Петрачков Д.В., Будзинская М.В., Павлов В.Г., Дуржинская М.Х., Халатян А.С. Нейродегенеративные биомаркеры ответа на терапию диабетического макулярного отека. Вестник офтальмологии 2020; 136(4):201-206. https://doi.org/10.17116/oftalma2020136042201</mixed-citation><mixed-citation xml:lang="en">Petrachkov DV, Budzinskaya MV, Pavlov VG, Durzhinskaya MH, Khalatyan AS. Neurodegenerative biomarkers of the response to diabetic macular edema treatment. Vestnik oftalmologii 2020; 136(4): 201-206. https://doi.org/10.17116/oftalma2020136042201</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Фурсова А.Ж., Гамза Ю.А., Дербенева А.С., Васильева М.С. Антиангиогенная терапия диабетического макулярного отека у пациентов с первичной открытоугольной глаукомой. Вестник офтальмологии 2020; 136(6):185-194. https://doi.org/10.17116/oftalma2020136062185</mixed-citation><mixed-citation xml:lang="en">Fursova AZh, Gamza YuA, Derbeneva AS, Vasilyeva MS. Anti-angiogenesis therapy of diabetic macular edema in patients with primary open-angle glaucoma. Vestnik oftalmologii 2020; 136(6):185-194. https://doi.org/10.17116/oftalma2020136062185</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol 2010; 21:178-183. https://doi.org/10.1097/ICU.0b013e328338679a</mixed-citation><mixed-citation xml:lang="en">Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol 2010; 21:178-183. https://doi.org/10.1097/ICU.0b013e328338679a</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011; 31:1449-1469. https://doi.org/10.1097/IAE.0b013e3182278ab4</mixed-citation><mixed-citation xml:lang="en">Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011; 31:1449-1469. https://doi.org/10.1097/IAE.0b013e3182278ab4</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">El Chehab H, Agard E, Russo A, Boujnah Y, Dot C. Intraocular Pressure Spikes after Aflibercept Intravitreal Injections. Ophthalmologica 2016; 236:43-47. https://doi.org/10.1159/000446878</mixed-citation><mixed-citation xml:lang="en">El Chehab H, Agard E, Russo A, Boujnah Y, Dot C. Intraocular Pressure Spikes after Aflibercept Intravitreal Injections. Ophthalmologica 2016; 236:43-47. https://doi.org/10.1159/000446878</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Лоскутов И.А., Мельникова Л.П., Калугина О.Н. Изменение офтальмотонуса на фоне эндовитреальных инъекций ингибиторов ангиогенеза. Национальный журнал глаукома 2017; 16(1):38-45.</mixed-citation><mixed-citation xml:lang="en">Loskutov I.A., Melnikova L.P., Kalugina O.N. Intraocular pressure after intravitreal injections of VEGF inhibitors. Natsional’nyi zhurnal glaukoma 2017; 16(1):38-45.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Еричев В.П., Тарасенков А.О., Андреева Ю.С. Офтальмогипертензия вследствие интравитреальных инъекций. Вестник офтальмологии 2022; 138(5 2):234 239. https://doi.org/10.17116/oftalma2022138052234</mixed-citation><mixed-citation xml:lang="en">Erichev VP, Tarasenkov AO, Andreeva YuS. Ocular hypertension after intravitreal injections. Vestnik oftalmologii 2022; 138(5 2):234 239. https://doi.org/10.17116/oftalma2022138052234</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hoguet, Philip P. Chen, Anna K. Junk, Prithvi Mruthyunjaya. The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma. Ophthalmology 2019; 126(4):611-622. https://doi.org/ 10.1016/j.ophtha.2018.11.019.</mixed-citation><mixed-citation xml:lang="en">Hoguet, Philip P. Chen, Anna K. Junk, Prithvi Mruthyunjaya. The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma. Ophthalmology 2019; 126(4):611-622. https://doi.org/ 10.1016/j.ophtha.2018.11.019.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 2007; 85:777-781. https://doi.org/10.1111/j.1600-0420.2007.00939.x</mixed-citation><mixed-citation xml:lang="en">Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 2007; 85:777-781. https://doi.org/10.1111/j.1600-0420.2007.00939.x</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cacciamani A, Oddone F, Parravano, et al. Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. Jpn J Ophthalmol 2013; 57:63e67. https://doi.org/10.1007/s10384-012-0194-8</mixed-citation><mixed-citation xml:lang="en">Cacciamani A, Oddone F, Parravano, et al. Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length. Jpn J Ophthalmol 2013; 57:63e67. https://doi.org/10.1007/s10384-012-0194-8</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kerimoglu H, Ozturk BT, Bozkurt B, Okka M, Okudan S. Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? Acta Ophthalmol (Copenh) 2011; 89:138-142. https://doi.org/10.1111/j.1755-3768.2009.01656.x</mixed-citation><mixed-citation xml:lang="en">Kerimoglu H, Ozturk BT, Bozkurt B, Okka M, Okudan S. Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? Acta Ophthalmol (Copenh) 2011; 89:138-142. https://doi.org/10.1111/j.1755-3768.2009.01656.x</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Бауэр С.М., Воронкова Е.Б., Котляр К.Е. О повышении внутриглазного давления после интравитреальных инъекций. Российский офтальмологический журнал 2021; 14(4):126-129. https://doi.org/10.21516/2072-0076-2021-14-4-126-129</mixed-citation><mixed-citation xml:lang="en">Bauer S.M., Voronkova E.B., Kotliar K.E. On elevation of intraocular pressure after intravitreal injections. Russian Ophthalmological Journal 2021; 14(4):126-129. https://doi.org/10.21516/2072-0076-2021-14-4-126-129</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ohji M, et al. Two different treat-and-extend dosing regimens of intravitreal aflibercept in Japanese patients with wet age-related macular degeneration: 96-week results of the ALTAIR study. Presented at 18th EURETINA congress, Vienna, 09.2018.</mixed-citation><mixed-citation xml:lang="en">Ohji M, et al. Two different treat-and-extend dosing regimens of intravitreal aflibercept in Japanese patients with wet age-related macular degeneration: 96-week results of the ALTAIR study. Presented at 18th EURETINA congress, Vienna, 09.2018.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Будзинская М.В., Плюхова А.А., Торопыгин С.Г. Современный взгляд на лечение экссудативной формы возрастной макулярной дегенерации. Вестник офтальмологии 2019; 135(5):107-115. https://doi.org/10.17116/oftalma2019135051107</mixed-citation><mixed-citation xml:lang="en">Budzinskaia MV, Pliukhova AA, Toropygin SG. Modern view on the treatment of wet-AMD patients. Vestnik oftalmologii 2019; 135(5): 107-115. https://doi.org/10.17116/oftalma2019135051107</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bakri SJ, Moshfeghi DM, Francom S, et al. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. Ophthalmology 2014; 121:1102-1108. https://doi.org/10.1016/j.ophtha.2013.11.029</mixed-citation><mixed-citation xml:lang="en">Bakri SJ, Moshfeghi DM, Francom S, et al. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. Ophthalmology 2014; 121:1102-1108. https://doi.org/10.1016/j.ophtha.2013.11.029</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Alkin Z, Perente I, Altan C, et al. Changes in anterior segment morphology after intravitreal injection of bevacizumab and bevacizumab-triamcinolone acetate combination. Eur J Ophthalmol 2013; 23:504-509. https://doi.org/10.5301/ejo.5000241</mixed-citation><mixed-citation xml:lang="en">Alkin Z, Perente I, Altan C, et al. Changes in anterior segment morphology after intravitreal injection of bevacizumab and bevacizumab-triamcinolone acetate combination. Eur J Ophthalmol 2013; 23:504-509. https://doi.org/10.5301/ejo.5000241</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wen J, Cousins S, Schuman S, Allingham R. Dynamic changes of the anterior chamber angle produced by intravitreal anti-vascular growth factor injections. Retina 2016; 36(10):1874-1881. https://doi.org/10.1097/IAE.0000000000001018</mixed-citation><mixed-citation xml:lang="en">Wen J, Cousins S, Schuman S, Allingham R. Dynamic changes of the anterior chamber angle produced by intravitreal anti-vascular growth factor injections. Retina 2016; 36(10):1874-1881. https://doi.org/10.1097/IAE.0000000000001018</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Будзинская М.В., Бубнова И.А., Кургузова А.Г., Фетцер Е.И. Изменения структур переднего отрезка глаза на фоне повышения внутриглазного давления после повторных интравитреальных инъекций. Вестник офтальмологии 2018; 134(5):156-161. https://doi.org/10.17116/oftalma2018134051156</mixed-citation><mixed-citation xml:lang="en">Budzinskaia MV, Bubnova IA, Kurguzova AG, Fettser EI. Structural changes in the ocular anterior segment against elevation of intraocular pressure after repeated intravitreal injections. Vestnik oftalmologii 2018; 134(5):156-161. https://doi.org/10.17116/oftalma2018134051156</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Quigley HA, Friedman DS, Congdon NG. Possible mechanisms of primary angle-closure and malignant glaucoma. J Glaucoma 2003; 12: 167-180. https://doi.org/10.1097/00061198-200304000-00013</mixed-citation><mixed-citation xml:lang="en">Quigley HA, Friedman DS, Congdon NG. Possible mechanisms of primary angle-closure and malignant glaucoma. J Glaucoma 2003; 12: 167-180. https://doi.org/10.1097/00061198-200304000-00013</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Guler M, Capkin M, Simsek A, et al. Short-term effects of intravitreal bevacizumab on cornea and anterior chamber. Curr Eye Res 2014; 39:989-993 https://doi.org/10.3109/02713683.2014.888452</mixed-citation><mixed-citation xml:lang="en">Guler M, Capkin M, Simsek A, et al. Short-term effects of intravitreal bevacizumab on cornea and anterior chamber. Curr Eye Res 2014; 39:989-993 https://doi.org/10.3109/02713683.2014.888452</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
